Therapeutics Pipeline

Explore our innovative development pipeline for gastrointestinal cancers.

TriAx/Bispecific Antibody Platform
Drug
Discovery
Preclinical
Phase 1
Phase 2
CDH17 / CD3 TCE
Basket GI cancers
Bispecific TCE
GI cancers
Undisclosed
Learn more
Trispecific TCE
Advanced GI cancers
Undisclosed
Learn more
Trispecific TCE
Advanced GI cancers
Antibody Drug Conjugate (ADC)
Drug
Discovery
Preclinical
Phase 1
Phase 2
ARB102A
FDA-approved drug
CDH17-positive tumors
Undisclosed
Bispecific ADC
CDH17-positive tumors
Undisclosed
Biparatopic ADC
CDH17-positive tumors
ARB103A
Photocaged drug
CDH17-positive tumors
Advanced Cell Therapy (CAR)
Drug
Discovery
Preclinical
Phase 1
Phase 2
ARB001
CAR-T
mCRC
ARB011
CAR-NK/T
Advanced GI cancers

Diagnostics Pipeline

Explore our innovative development pipeline for gastrointestinal cancers.

Platform
Intended Use
Prototyping / Optimization
Manufacturing
Clinical Studies
Launch
CDH17 - IHC Test
GI cancer diagnostics
CDH17 - Blood Test
CRC screening / surveillance
CDH17 - POCT
Point-of-Care Test

Join our research

Explore our pipeline

Discover our groundbreaking immunotherapy platforms for gastrointestinal cancers.